FAP and cardiomyopathy: Treatment benefits of inotersen were observed for NIS and NIS-LL total and muscle weakness scores, as well as NIS sensation scores, across patient subgroups based on genetic mutation, FAP disease stage, previous treatment, cardiomyopathy status, and age of symptom onset.